Crossject has announced it has raised €14m in debt to finance its expansion.
Crossject has announced it has raised €14m in debt to finance its expansion.FINANCING ISSUE
The group has raised €14m in new debt, securing the group’s financing ahead of product launches.
We appreciate that it did not have to resort to dilutive instruments.
Since this had been our assumption, no change to our numbers or valuation.
The upside potential remains very significant.
FACT
Crossject has announced it has raised €14m in debt to finance its expansion.
ANALYSIS
The group has announced it has reached an agreement with its historical banks (Caisse d’Epargne and BNP) as well as Société Générale and BPI to raise €14m in debt at maturities ranging from 5 to 10 years. This news comes as a relief, since this means that the group has the firepower to finance its expansion for FY2023, with the first product launches expected this year (Emergency Use Utilization) and the likely market approval of Midazolam in the US (FY23 or FY24).
This also confirms the confidence of the banks in the group’s future and will prevent potential further dilution. Lastly, this is in line with the previous statement from the management according to which they will, as far as possible, avoid resorting to dilutive instruments to fuel growth. Note that, to finance the group’s development, the number of outstanding shares has actually steadily risen in the past few years, from 8.8m in FY17 to 36.35m currently. This is thus good news in that there is no risk of shareholders being further diluted.
IMPACT
No changes to our numbers following this news since they had already factored in bank financing as opposed to the issuance of new dilutive instruments.
Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
AlphaValue Corporate Services capitalise on the research and credit analysis expertise deployed by AlphaValue with major institutional investors at European level over the past nine years. The proprietary tools and processes enabling AlphaValue Corporate Services to establish a valuation and/or a credit risk assessment are identical to those used by AlphaValue to the benefit of its institutional clients. The only difference is the recognition that a company evaluation cannot be dissociated from the fact that the latter is paying for the service (AlphaValue Corporate Services), as opposed to the investor footing the bill (AlphaValue). AlphaValue’s research tools are characterised by the transparency of the valuation methodologies, their responsiveness to market data and by nine years’ experience of a universe numbering more than 450 European companies. Through its coverage and sector exhaustiveness, AlphaValue ranks alongside the major research houses in Europe and constitutes the only new entrant to the European space in the past decade. This significant presence is reflected in an unrivalled distribution capability via platforms commonly adopted by investors to access research: Factset, Bloomberg, Capital IQ and the numerous websites. AlphaValue is one the largest research contributors to these platforms, to the benefit of AlphaValue Corporate Services issuer clients. The AlphaValue Corporate Services analysts are AlphaValue’s sector specialists. Their robust knowledge of the business models in their sectors enables the rapid generation of incisive, relevant research and advantageous interaction with the management teams.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.